Chen, R., Palmer, J. M., Thomas, S. H., Tsai, N., Farol, L., Nademanee, A., . . . Gopal, A. K. (2012). Brentuximab vedotin enables successful reduced-intensity allogeneic hematopoietic cell transplantation in patients with relapsed or refractory Hodgkin lymphoma. American Society of Hematology.
Citação norma ChicagoChen, Robert, Joycelynne M. Palmer, Sandra H. Thomas, Ni-Chun Tsai, Len Farol, Auayporn Nademanee, Stephen J. Forman, and Ajay K. Gopal. Brentuximab Vedotin Enables Successful Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed or Refractory Hodgkin Lymphoma. American Society of Hematology, 2012.
Citação norma MLAChen, Robert, et al. Brentuximab Vedotin Enables Successful Reduced-intensity Allogeneic Hematopoietic Cell Transplantation in Patients With Relapsed or Refractory Hodgkin Lymphoma. American Society of Hematology, 2012.